The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Niraparib in BAP1 and DDR pathway deficient solid tumors
Brian H. Ramnaraign, MD, University of Florida College of Medicine, Gainesville, FL, discusses the rationale of an ongoing Phase II trial investigating the PARP inhibitor, niraparib, in BRCA-1 associated Protein 1 (BAP1) and other DNA damage response (DDR) pathway deficient neoplasms, including patients with cholangiocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
